134 related articles for article (PubMed ID: 35150898)
1. To Scan or Not to Scan: The Dilemma of Posttreatment Imaging Surveillance of Head and Neck Cancer.
Janopaul-Naylor JR; Aiken AH; Saba NF; El-Deiry M; Kaka AS; Stokes WA
Pract Radiat Oncol; 2022; 12(3):210-214. PubMed ID: 35150898
[TBL] [Abstract][Full Text] [Related]
2. Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines.
Mehanna H; Kong A; Ahmed SK
J Laryngol Otol; 2016 May; 130(S2):S181-S190. PubMed ID: 27841130
[TBL] [Abstract][Full Text] [Related]
3. Posttreatment Head and Neck Cancer Imaging: Anatomic Considerations Based on Cancer Subsites.
Hiyama T; Miyasaka Y; Kuno H; Sekiya K; Sakashita S; Shinozaki T; Kobayashi T
Radiographics; 2024 Mar; 44(3):e230099. PubMed ID: 38386602
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up.
Imbimbo M; Alfieri S; Botta L; Bergamini C; Gloghini A; Calareso G; Orlandi E; Iacovelli NA; Guzzo M; Granata R; Resteghini C; Locati L; Volpi CC; Licitra L; Bossi P
Otolaryngol Head Neck Surg; 2019 Oct; 161(4):635-642. PubMed ID: 31286827
[TBL] [Abstract][Full Text] [Related]
5. PET/Computed Tomography: Post-therapy Follow-up in Head and Neck Cancer.
You H; Subramaniam RM
PET Clin; 2022 Apr; 17(2):319-326. PubMed ID: 35256299
[TBL] [Abstract][Full Text] [Related]
6. Posttreatment Imaging in Patients with Head and Neck Cancer without Clinical Evidence of Recurrence: Should Surveillance Imaging Extend Beyond 6 Months?
Gore A; Baugnon K; Beitler J; Saba NF; Patel MR; Wu X; Boyce BJ; Aiken AH
AJNR Am J Neuroradiol; 2020 Jul; 41(7):1238-1244. PubMed ID: 32554418
[TBL] [Abstract][Full Text] [Related]
7. Negative predictive value of surveillance PET/CT in head and neck squamous cell cancer.
McDermott M; Hughes M; Rath T; Johnson JT; Heron DE; Kubicek GJ; Kim SW; Ferris RL; Duvvuri U; Ohr JP; Branstetter BF
AJNR Am J Neuroradiol; 2013 Aug; 34(8):1632-6. PubMed ID: 23639557
[TBL] [Abstract][Full Text] [Related]
8. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
9. Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study.
Van den Wyngaert T; Helsen N; Carp L; Hakim S; Martens MJ; Hutsebaut I; Debruyne PR; Maes ALM; van Dinther J; Van Laer CG; Hoekstra OS; De Bree R; Meersschout SAE; Lenssen O; Vermorken JB; Van den Weyngaert D; Stroobants S;
J Clin Oncol; 2017 Oct; 35(30):3458-3464. PubMed ID: 28854069
[TBL] [Abstract][Full Text] [Related]
10. PET-CT and the detection of the asymptomatic recurrence or second primary lesions in the treated head and neck cancer patient.
Dunsky KA; Wehrmann DJ; Osman MM; Thornberry BM; Varvares MA
Laryngoscope; 2013 Sep; 123(9):2161-4. PubMed ID: 23817791
[TBL] [Abstract][Full Text] [Related]
11.
Wong ET; Dmytriw AA; Yu E; Waldron J; Lu L; Fazelzad R; de Almeida JR; Veit-Haibach P; O'Sullivan B; Xu W; Huang SH
Head Neck; 2019 Feb; 41(2):551-561. PubMed ID: 30456825
[TBL] [Abstract][Full Text] [Related]
12. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report.
Yao M; Graham MM; Smith RB; Dornfeld KJ; Skwarchuk M; Hoffman HT; Funk GF; Graham SM; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1410-8. PubMed ID: 15590172
[TBL] [Abstract][Full Text] [Related]
13.
Kim SA; Roh JL; Kim JS; Lee JH; Lee SH; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2017 Feb; 72():62-70. PubMed ID: 28027517
[TBL] [Abstract][Full Text] [Related]
14. Surveillance for recurrent head and neck cancer using positron emission tomography.
Lowe VJ; Boyd JH; Dunphy FR; Kim H; Dunleavy T; Collins BT; Martin D; Stack BC; Hollenbeak C; Fletcher JW
J Clin Oncol; 2000 Feb; 18(3):651-8. PubMed ID: 10653881
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy.
Chaiken L; Rege S; Hoh C; Choi Y; Jabour B; Juillard G; Hawkins R; Parker R
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):455-64. PubMed ID: 8407422
[TBL] [Abstract][Full Text] [Related]
16. The role of positron emission tomography/CT imaging in head and neck cancer patients after radical chemoradiotherapy.
Sherriff JM; Ogunremi B; Colley S; Sanghera P; Hartley A
Br J Radiol; 2012 Nov; 85(1019):e1120-6. PubMed ID: 22744325
[TBL] [Abstract][Full Text] [Related]
17. Use of Diffusion-Weighted Imaging and
Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
[TBL] [Abstract][Full Text] [Related]
18. Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring.
Beswick DM; Gooding WE; Johnson JT; Branstetter BF
Laryngoscope; 2012 Jul; 122(7):1512-7. PubMed ID: 22685038
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of First Posttreatment Imaging Using Standardized Reporting in Head and Neck Cancer.
Hsu D; Chokshi FH; Hudgins PA; Kundu S; Beitler JJ; Patel MR; Aiken AH
Otolaryngol Head Neck Surg; 2019 Dec; 161(6):978-985. PubMed ID: 31331239
[TBL] [Abstract][Full Text] [Related]
20. ACR Neck Imaging Reporting and Data Systems (NI-RADS): A White Paper of the ACR NI-RADS Committee.
Aiken AH; Rath TJ; Anzai Y; Branstetter BF; Hoang JK; Wiggins RH; Juliano AF; Glastonbury C; Phillips CD; Brown R; Hudgins PA
J Am Coll Radiol; 2018 Aug; 15(8):1097-1108. PubMed ID: 29983244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
